Information about Actos and bladder cancer.
Welcome

Consumer Reports warns against generic version of Actos

September 7th, 2012

Consumer Reports has warned readers against using a generic version of Actos recently approved by the Food and Drug Administration. The consumer awareness organization recommends that patients ask their doctors if using the brand-name diabetes drug Actos or its new generic equivalent is necessary, and recommends it only for patients who have no other options.

The FDA issued a warning in August 2011 that taking the drug could lead to an increased risk of developing serious side effects. A five-year study of the drug indicated that patients who use the drug for more than one year could be 40% more likely to develop bladder cancer.

Actos is a type II diabetes medication that was first introduced by Takeda Pharmaceuticals. Several Actos bladder cancer lawsuits have been filed against the company, alleging that it failed to warn doctors and patients of the increased risks. Lawyers involved with the cases predict the company could face as many as 10,000 Actos lawsuits.

Contact Us Today for a Free Consultation.

YesNo
I am currently represented by an attorney.
captcha
*Required fields